Adoptive Immunotherapy of a Rat Glioma Using Lymphokine-activated Killer Cells and Interleukin 2

摘要: The aim of the present study was to develop an animal model test therapeutic potential purified adherent lymphokine-activated killer (A-LAK) cells against intracerebrally implanted rat glioma, designated F98. Highly A-LAK demonstrated greater activity F98 tumor than conventional cells, as determined by means 51Cr-release and clonogenic assays. Therapeutic efficacy evaluated a Winn neutralization assay, in which targets or control nonadherent mononuclear were incubated for 18 h vitro then stereotactically into right caudate nuclei Fischer rats. Animals given injections 4000 alone had mean survival time 22.3 days, compared 46.1 days ( P < 0.001) rats treated with cells. Increasing inoculum 12,500 reduced A-LAK-treated animals 27.8 20.8 untreated controls. Systemic administration 50,000 units/kg interleukin 2 every 12 5 failed improve survival. ranged from 16 105 29 102 Extrapolating these data, treatment may have decreased number <10, but even this small still lethal. Supernatants immunoinhibitory that, further, modulated antitumor effects Our results indicate that curative, adoptive immunotherapy glioma A-LAK/interleukin is impossible achieve provide some explanation clinical failures been observed malignant gliomas.